MOSCOW (Reuters) – Russia will begin Phase III trials of a second potential vaccine against COVID-19, developed by Siberia’s Vector Institute, in November-December, the TASS news agency cited Russian consumer safety watchdog Rospotrebnadzor as saying on Friday.
Early-stage clinical trials for the vaccine were completed on Wednesday.
(Writing by Alexander Marrow; Editing by Polina Ivanova)
Oilers captain Connor McDavid becomes 4th player in NHL history to record 100 assists in a season
Jackie Robinson remembered around MLB on 77th anniversary of him breaking baseball’s color barrier
Artemi Panarin scores 49th goal as Rangers beat Senators 4-0 to clinch Presidents’ TrophyBader drives in go-ahead run for second straight day as Mets beat Pirates 6-3 to reach .500 at 8-8Islanders beat Devils to clinch playoff berth, 3rd place in Metro division
Fire rages through the 17th-century Old Stock Exchange in Copenhagen, toppling the iconic spire
Biden administration announces new partnership with 50 countries to stifle future pandemics
Greece plans 2 marine protected areas as part of an $830 million environmental protection program
Tensions rise in Australia after a bishop and priest are wounded in a knife attack in a church
Despite weather glitch, the Paris Olympics flame is lit at the Greek cradle of ancient games
Biden administration announces new partnership with 50 countries to stifle future pandemics
Indiana limits abortion data for privacy under near-total ban, but some GOP candidates push back
Weedkiller manufacturer seeks lawmakers’ help to squelch claims it failed to warn about cancer
New rules for Pregnant Workers Fairness Act include divisive accommodations for abortion
